The gov's all-out efforts to promote EUA for overseas drugs

Please prescribe an appropriate amount of medicine and use solid ingredients instead of syrup

Continuing administrative support for rapid production and shipment...cooperation with the pharmaceutical industry in stabilizing supply

The government will make all-out efforts to expand the total amount of supply by expanding the production and import of regular medicines such as antipyretic painkillers and cold medicines used to alleviate COVID-19 symptoms.

 

It will even review the emergency introduction of foreign drugs with the same composition as domestic licensed items, quickly review them to prevent disruptions in production due to administrative procedures such as permits, and continue administrative support.

 

The government expressed its willingness to make active efforts with the pharmaceutical industry to stabilize the supply of COVID-19, while also asking the medical and pharmaceutical sectors for cooperation such as prescribing an appropriate amount of solid drugs instead of syrup.

 

Park Hyang, head of the Central Disaster and Safety Countermeasures Headquarters, made the announcement at a regular briefing on the 23rd.

 

As a result of receiving a report from the MFDS on the supply and demand status and action plans for COVID-19, the Central Disaster and Safety Countermeasures Headquarters decided that supply needs to be stabilized.

 

The shortage of some products of antipyretic pain relievers and cold medicines used to alleviate COVID-19 symptoms continues.

 

Accordingly, the government will expand the total supply of COVID-19 medicines.

 

Specifically, it expands production and imports and encourages rapid shipment.

 

It will consider promoting the emergency introduction of overseas drugs with the same composition as domestic licensed products.

 

The government plans to do its best to prevent disruptions in production by providing support for rapid processing such as changing the raw materials and manufacturing plants of standing medicines, quick import approval of drugs and raw materials contained in cold medicines, and convenience of other administrative procedures.

 

It also asked the medical and pharmaceutical sectors to prescribe an appropriate amount of prescription and a solid drug rather than a syrup drug.

 

The government announced its intention to maintain and strengthen support for clinical trials of COVID-19 vaccines and treatments.

 

Currently, eight vaccine companies and 17 treatment companies (18 candidate substances) are conducting clinical trials in Korea.

 

SK Bioscience vaccine has completed recruiting and inoculating phase 3 clinical participants with the aim of completing development in the first half of this year.

 

Subsequently, the procedure for confirming the efficacy of the vaccine through sample analysis is in progress.

 

The treatment is developing an additional antibody treatment (Celltrion) that can respond to mutant viruses, and Ildong Pharmaceutical is jointly conducting clinical trials by securing domestic copyright for Shionogi's developed and edible treatments.

 

The government announced that it is supporting the development of domestic COVID-19 vaccines and treatments with all its might by operating the pan-government support committee for the development of COVID-19 treatments and vaccines.

 

The government said, "For the rapid development of treatments and vaccines, clinical trials are more important than anything else," adding, "We ask the public to actively pay attention to and participate in clinical trials."